SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001136261-22-000210
Filing Date
2022-05-10
Accepted
2022-05-10 16:17:15
Documents
66
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 body10-q.htm   iXBRL 10-Q 1044899
7 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER exh31-1.htm EX-31.1 10337
8 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS exh32-1.htm EX-32.1 3248
9 CERTIFICATION OF CHIEF FINANCIAL OFFICER exh31-2.htm EX-31.2 10330
10 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS exh32-2.htm EX-32.2 3261
  Complete submission text file 0001136261-22-000210.txt   4953266

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE seel-20220331.xsd EX-101.SCH 34458
3 XBRL CALCULATION FILE seel-20220331_cal.xml EX-101.CAL 38511
4 XBRL DEFINITION FILE seel-20220331_def.xml EX-101.DEF 194948
5 XBRL LABEL FILE seel-20220331_lab.xml EX-101.LAB 289619
6 XBRL PRESENTATION FILE seel-20220331_pre.xml EX-101.PRE 275824
60 EXTRACTED XBRL INSTANCE DOCUMENT body10-q_htm.xml XML 684563
Mailing Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 (646) 293-2100
SEELOS THERAPEUTICS, INC. (Filer) CIK: 0001017491 (see all company filings)

IRS No.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22245 | Film No.: 22909880
SIC: 2834 Pharmaceutical Preparations